US$ 27.87
oral glp-1 agonist approved Comparing Ozempic, Wegovy and Other Drugs Removing the needle: the unmet
Description
Counteraction of GLP-1 effect on gastric emptying by co-infusion with prokinetic drug erythromycin during a liquid test meal diminished GLP-1s ability to decrease postprandial hyperglycemia in patients with T2DM (153)

LTP, long-term enhancement
The primary active ingredient in Ozempic is semaglutide

The incretin/glucagon system as a target for pharmacotherapy of obesity

Those older drugs were effective but carried side effects that limited their use
Grateful to my mentors, co-authors, and the journal editorial team for their support throughout this journey
